CELEBRATING 24 YEARS IN BUSINESS OVER 300,000 CLIENTS REPRESENTED
A relatively new class of drugs known as sitagliptin includes the brand name Januvia and is used in the treatment of type 2 diabetes. Januvia—along with others in the same class—has been shown in some studies to bring significant risks to patients taking the drug. Januvia blocks or inhibits DPP-4 in the body, allowing the patient’s system to better control glucose levels as well as increasing the amount of insulin produced by the pancreas when the blood sugar is high. These DPP-4 blockers can also reduce the amount of sugar produced by the liver when the body does not need the excess.
WARNING: Do not send any information in any email through this website if you consider the information confidential or privileged.
STARS ON YELP WITH OVER 400 REVIEWS*
*AS OF 2024
TOP 10 VERDICT IN TEXAS* 2022
*BY TOPVERDICT.COM
TOP 100 NATIONAL TRIAL LAWYER* 2013-2025
*BY THE NATIONAL TRIAL LAWYERS
AVVO CLIENT'S CHOICE AWARD* 2016, 2017, 2019-2024
*GIVEN BY AVVO
AMERICAN ASSOCIATION OF JUSTICE 2013-2024
*GRANTED BY THE AAJ